Innate Pharma (IPHA) Current Assets (2017 - 2025)

Innate Pharma (IPHA) has reported Current Assets for 9 consecutive years, with $53.2 million the latest figure, recorded in Q4 2025.

• Quarterly Current Assets fell 45.52% year-over-year to $53.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $53.2 million (down 45.52% YoY) and the FY2025 annual result came in at $53.2 million, down 45.52% from the prior year.
• Current Assets eased to $53.2 million in Q4 2025 per IPHA's latest filing, from $73.9 million in the prior quarter.
• Over the last five years, Current Assets for IPHA reached as high as $195.5 million in Q2 2022 and fell as low as $53.2 million in Q4 2025.
• A 5-year average of $134.4 million and a median of $152.5 million in 2021 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2021 — Current Assets plunged 99.91% — and 2022, when it surged 32.47%.
• Year by year, Current Assets stood at $157.3 million in 2021, then climbed by 1.14% to $159.1 million in 2022, then rose by 5.85% to $168.4 million in 2023, then tumbled by 42.07% to $97.6 million in 2024, then slumped by 45.52% to $53.2 million in 2025.
• According to Business Quant data, Current Assets over the past three periods registered $53.2 million, $73.9 million, and $97.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.